The Full Text of Novo Nordisk's Recent Warning Letters, Read for Patients

Novo Nordisk's outbound legal correspondence to compounders and telehealth marketers is generally not made public in full text, but sample letters and pleadings from resulting litigation give the substance. Here's what the letters actually argue and what that means for patients using named platforms.

The Core Legal Theories

The letters generally cite three legal theories. First, trademark infringement: use of Wegovy or Ozempic brand names in marketing for compounded product. Second, false advertising: claims of equivalence between compounded product and the FDA-approved branded medication. Third, unfair competition: implying manufacturer endorsement or product identity where none exists.

These aren't fringe theories. They reflect standard trademark and consumer-protection law, and Novo's positions on them are legally conventional. The interesting question is which specific practices trigger the letters — that's what patients can learn from actually reading the language.

What Triggers a Letter

Practices commonly cited include: landing pages that use "Wegovy" or "Ozempic" as marketing headers for compounded product; ad copy that says "same as Wegovy but cheaper"; testimonials attributing compounded product benefits using brand-name language; and metadata (SEO tags, page titles) that ranks for brand-name searches while promoting compounded alternatives.

Practices that generally don't trigger letters: neutral educational content that references brand names for context; comparison articles that clearly distinguish brand and compounded; and marketing that promotes the compounded product on its own terms without brand-name reference.

What Recipients Actually Do

Most letters resolve without litigation. Recipient companies typically respond by modifying marketing to remove the flagged practices, sometimes negotiate a written agreement, and continue operations. This is the standard outcome — cease-and-desist letters are opening moves in a negotiation, not immediate ultimatums.

Recipients that don't comply, or that continue practices after receiving letters, are more likely to face actual lawsuits with injunctive relief requested. Those cases can affect operations more materially and are where patients see program disruption.

What This Means for Patients

If your compounded GLP-1 platform receives a Novo cease-and-desist, that's not automatically a signal to switch providers. Most letters resolve with marketing changes and no operational impact on medication supply. What's worth watching: does the platform's marketing quietly change? Does the platform respond publicly? Does the platform reach out to patients proactively about continuity plans? Transparent response is a good signal; silence is worth noting.

Programs that continue to use Novo's brand names aggressively despite receiving letters are the ones at higher risk of eventual litigation-driven disruption. That's information worth having when evaluating provider stability.

The Legitimate Compounding Practice

Well-run compounders can operate legally in the current environment by tightening marketing language, documenting patient-specific personalization on prescriptions, and avoiding brand-name comparisons. Programs that do these things are generally more stable in the current legal environment than programs that rely on brand-name marketing hooks.

Where to Start